Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted therapy alone in 23%, reflecting heterogeneous, risk- and access-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results